Ondine Biomedical, a global leader in photodisinfection technologies for the prevention and treatment of viral, bacterial, and fungal infections, will present new research highlighting advances in its technology at the American Society for Microbiology (ASM) Microbe conference, taking place in Washington, D.C., June 22–25. ASM Microbe is the world’s largest microbiology conference.
The poster, titled “MB-PDT and Chlorhexidine Time-Kill Approach for Determining Synergy,” presents a novel method for evaluating how Methylene Blue-based photodynamic therapy (MB-PDT) works in combination with chlorhexidine, a widely used antiseptic. The research introduces a new time-kill methodology to assess the synergistic effects of the two treatments and their potential to improve antimicrobial efficacy and sustained in vitro outcomes.
The findings suggest that combining MB-PDT with chlorhexidine may enhance antimicrobial effectiveness and support stronger infection prevention strategies. By demonstrating how these complementary approaches can work together, the research highlights new opportunities to strengthen infection control protocols and combat antimicrobial resistance.
Ondine’s photodisinfection technology is now widely used in Canada and the UK, both prior to surgery and in ICUs, to prevent infections without generating resistance. In the US, the company has just completed its pivotal Phase 3 trial for FDA submission.
No comments yet